LIPOSOMAL GM1 – a regenerative therapy approach for Parkinson’s disease
To improve the current treatment options for Parkinson’s patients, a medication is needed that tackles the disease as close to its cause as possible and supports the body’s own production of dopamine, which is limited by Parkinson’s disease, in the long term. InnoMedica’s latest development project uses the liposomal transport system to deliver a nerve cell regenerating agent into the brain.
Current research on Parkinson’s shows that GM1 as a brain component is able to promote the survival and regeneration of damaged nerve cells. In a human study with 94 Parkinson’s patients, the active substance achieved a strong immediate and long-lasting effect. In this study, however, the drug had to be administered subcutaneously twice a day in order to accumulate sufficient amounts of GM1 in the brain for a therapeutic effect. These injections caused painful local skin reactions, which despite the strong symptom improvement usually were unbearable for the patient. This method of administration is not used therapeutically due to the severe side effects.
InnoMedicas Talineuren combines the potential of GM1 in Parkinson’s therapy with the advantages of liposomal technology. Contrary to the widespread scientific assumption that liposomes cannot penetrate into the brain, InnoMedica was able to determine a specific composition of the liposome, which allows a crossing of the blood-brain barrier and thus brings drugs directly into the brain. The preclinical data of InnoMedicas Talineuren show the following advantages:
The active substance used is a natural component of nerve cells and does not only fight symptoms of Parkinson’s, but also has a regenerative effect on the brain. Instead of fighting symptoms, a therapy that can positively inﬂuence the course of the disease in the long term becomes possible.
Few side effects
The medications used today to fight Parkinson’s symptoms often cause serious side effects. In the preclinical studies with Talineuren, no side effects of the product have been observed so far.
Talineuren can be delivered in a vial and drunk by the patient. Oral administration has the advantage that, unlike injections, the therapy is pain-free and can be administered without medical help. This means treatment is simpler with significantly less intervention in the patient’s daily routine.
The protective and regenerative properties of this treatment method are novel in the context of the therapies available today for neurological disorders.
In order to gain a better understanding of the mechanism of action of Talineuren, further studies are planned. InnoMedica is convinced that Talineuren will be a long-term effective therapy which, with its regenerative approach and simple oral administration, will fundamentally improve the treatment of Parkinson’s patients.
InnoMedica is now organizing a team of doctors and scientists to bring Talineuren into the clinic. Furthermore, cooperations with larger pharmaceutical companies are being evaluated for this project. InnoMedica has a good starting position in these negotiations, since a patent has been fled for this application at the end of December 2017.